15 April 2019
Visiongain has launched a new pharma report Top 25 Dermatological Drugs Manufacturers: Galderma, Johnson & Johnson, AbbVie, GlaxoSmithKline, Pfizer, Novartis, Eli Lilly, Mylan, Other Companies.
Dermatological drugs market has been growing over the last decade. A combination of significant new market launches and corporate activities has changed the outlook of the pharmaceutical industry towards this market. The dermatological drugs market in 2018 was reported to be US$ 26.23bn. Visiongain’s analysis of the market shows Humira, Stelara, Enbrel, Remicade, Otezla and Cosentyx among the top dermatological drugs driving the market at present.
The lead analyst of the report commented "The dermatological drugs market has in the past been the domain of small and medium-sized pharma companies specialising in dermatology and perhaps a few other therapeutic areas. Although the development of biological therapies has changed this perception somewhat, it remains likely that future dermatological drug development will be driven by innovation from small biopharmaceutical companies. Many of the novel products in the development pipeline have come from small companies targeting new treatment pathways or mechanisms of action.
We note however that the dermatological drugs market is a diverse one, which presents opportunities for large pharma companies also. Development of biologic therapies in this market may be a lucrative business opportunity for big pharma companies over the next decade. One way into the market will be to license pipeline candidates from smaller companies. This is already a common strategy in this sector of the market, and within the pharma industry as a whole. Alternatively, a strategy of targeted acquisitions provides opportunities for larger pharmaceutical companies to enter into the dermatological drugs market."
Leading companies featured in the report include Abbvie Inc., Allergan plc, Almirall S.A., Amgen, Astellas, Bayer, Concert Pharmaceuticals, Eli Lilly and Company, Galderma, GlaxoSmithkline plc (GSK), Johnson & Johnson (J&J), Leo Pharma A/S, Lupin Ltd and other companies.
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to email@example.com or call her on + 44 (0) 20 7549 9987.
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.
Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.
The Macular Degeneration (AMD) and Other Retinal Diseases Drugs market was valued at US$25.29 billion in 2021 and is projected to grow at a CAGR of 7.87% during the forecast period 2022-2032.
25 November 2022
Pharmaceutical Contract Manufacturing Organisations (CMOs) market is projected to grow at a CAGR of 6.9% by 2032.
25 November 2022
The Dermatology CROs market was valued at US$ 5,154.8 million in 2021 and is projected to grow at a CAGR of 8.7% during the forecast period 2022-2032.
23 November 2022
The Direct-to-Patient market was valued at US$38,651 million in 2021 and is projected to grow at a CAGR of 6.1% during the forecast period 2022-2032.